The Supreme Court upheld a Delhi High Court order restraining Flipkart from using its “MarQ” electronics brand, ruling the mark is substantially similar to Marc Enterprises’ “Marc” trademark in pronunciation and overall commercial impression. The Court warned the use of such close marks would cause confusion, and refused to interfere with interim orders. Flipkart has eight weeks to dispose of remaining inventory. The dispute spans products sold online since 2017, with Marc’s trademark use dating back to 1981.
The Bombay High Court ruled in favour of Sun Pharmaceutical Industries in a trademark dispute against United Biotech. It restrained United Biotech from using a similar mark, holding that Sun Pharma’s “Octride” has the stronger claim. The case relates to drugs used for acromegaly and carcinoid tumours, with the judgment protecting Sun’s reputation and goodwill.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
UltraTech Cement has won a trademark battle in the Bombay High Court, which barred Shiv Cement Co. from using the “UltraPlus” and “UltraHiTouch” brands. The court ruled the rival’s trademarks were confusingly similar to UltraTech’s well-known products. Shiv Cement Co. has been ordered to pay Rs 50 lakh in compensation plus Rs 16.48 lakh toward legal costs.
Sun Pharmaceutical has won a trademark dispute in Bombay High Court, which barred Meghmani Lifesciences from using the drug mark “Esiraft.” The court accepted Sun’s claim that Meghmani’s “Esiraft” is visually and phonetically similar to Sun’s “Raciraft,” creating a strong likelihood of consumer confusion and amounting to infringement and passing off.
The Bombay High Court has barred a Navi Mumbai drugmaker from using the brand names “Absun” and “Absun Pharma,” siding with Sun Pharmaceutical Industries. In a long-running trademark dispute, the court ruled the competing names are deceptively similar to Sun Pharma’s established marks, potentially confusing consumers. The verdict effectively ends the decade-long legal battle.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
